Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Krystal Biotech ( (KRYS) ) has issued an update.
On December 22, 2025, Krystal Biotech announced that board member Kirti Ganorkar had submitted his resignation from the company’s Board of Directors, effective December 31, 2025. Ganorkar, who has served on the board since Krystal’s public listing in September 2017, is stepping down due to time constraints following his recent promotion to Managing Director at Sun Pharma, with the company emphasizing that his departure is not related to any disagreement over its operations, policies, or practices and publicly thanking him for his years of service and contributions.
The most recent analyst rating on (KRYS) stock is a Buy with a $278.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.
Spark’s Take on KRYS Stock
According to Spark, TipRanks’ AI Analyst, KRYS is a Outperform.
Krystal Biotech’s strong financial performance and successful international expansion are the most significant factors driving the stock’s positive outlook. The company’s robust earnings call and strategic corporate events further bolster confidence. However, technical indicators suggest caution due to potential short-term overbought conditions, and the high valuation reflects expectations of continued growth.
To see Spark’s full report on KRYS stock, click here.
More about Krystal Biotech
Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines, operating in the biopharmaceutical industry with an emphasis on innovative therapies for serious diseases.
Average Trading Volume: 309,106
Technical Sentiment Signal: Buy
Current Market Cap: $6.98B
Learn more about KRYS stock on TipRanks’ Stock Analysis page.